Another Biogen Alzheimer's drug expedited by the FDA

Just weeks after winning approval from the U.S. Food and Drug Administration for its Alzheimer's drug Aduhelm — a decision that continues to be mired in controversy — Biogen Inc. (Nasdaq: BIIB) has scored breakthrough therapy designation for another, similar drug called lecanemab.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.